ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced two distinguished biopharmaceutical veterans to lead the Company: David Marek appointed as Chief Executive Officer and Paolo Martini, Ph.D., appointed as Chief Research and Development Officer.
“As ReAlta evolves into a late-stage development company with multiple clinical programs spanning three distinct therapeutic areas with significant unmet need, I am confident that David and Paolo are the ideal leaders for these two pivotal roles,” said Edward A. Heidt, Jr., Chairperson of ReAlta’s Board of Directors. “David has a strong track record of success driving business transformation including leading an organization with one of the most successful buyouts in recent years, while Paolo’s deep expertise in leading-edge drug discovery and development across an array of therapeutic areas, including rare diseases, will position ReAlta well as we look ahead to delivering potentially life-saving medications for patients with rare and acute inflammatory diseases.”
“It’s rare to find a company so well positioned with a novel scientific approach to take on one of the great challenges in human health – inflammation. Although a key aspect of the body’s immune defenses, inflammation also has significant involvement in the disease process of many conditions and diseases that account for more than half of all deaths globally,” said Mr. Marek. “I am excited to bring my energy and experience to serve as the CEO of ReAlta and am proud to work alongside team members who work tirelessly to break new ground in advancing our mission on behalf of patients.”
“The design of ReAlta’s investigational medicines are inspired by nature – specifically a human enteric virus which has adapted over one billion years of evolution to mitigate inflammation through a dual targeting mechanism that modulates both complement and innate inflammatory pathways. By inhibiting activation of the complement cascade and the neutrophil-driven mechanisms of inflammation and host tissue destruction, ReAlta’s EPICC peptide platform has the potential to provide new hope for patients with rare and acute inflammatory diseases,” said Dr. Martini. “I look forward to advancing our pipeline and to unlocking new opportunities alongside the ReAlta team.”
Learn more here.